162 related articles for article (PubMed ID: 8734460)
1. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure.
Niwa T
Semin Nephrol; 1996 May; 16(3):167-82. PubMed ID: 8734460
[TBL] [Abstract][Full Text] [Related]
2. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
[TBL] [Abstract][Full Text] [Related]
3. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
4. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
[TBL] [Abstract][Full Text] [Related]
5. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.
Niwa T; Aiuchi T; Nakaya K; Emoto Y; Miyazaki T; Maeda K
Clin Nephrol; 1993 Feb; 39(2):92-6. PubMed ID: 8448924
[TBL] [Abstract][Full Text] [Related]
7. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.
Niwa T; Ise M
J Lab Clin Med; 1994 Jul; 124(1):96-104. PubMed ID: 8035108
[TBL] [Abstract][Full Text] [Related]
8. Update of uremic toxin research by mass spectrometry.
Niwa T
Mass Spectrom Rev; 2011; 30(3):510-21. PubMed ID: 21328600
[TBL] [Abstract][Full Text] [Related]
9. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
10. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition.
Nishio T; Takamura N; Nishii R; Tokunaga J; Yoshimoto M; Kawai K
Nephrol Dial Transplant; 2008 Jul; 23(7):2304-10. PubMed ID: 18390890
[TBL] [Abstract][Full Text] [Related]
11. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys.
Miyazaki T; Ise M; Seo H; Niwa T
Kidney Int Suppl; 1997 Nov; 62():S15-22. PubMed ID: 9350672
[TBL] [Abstract][Full Text] [Related]
12. Uremic toxicity of indoxyl sulfate.
Niwa T
Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
[TBL] [Abstract][Full Text] [Related]
13. Removal of protein-bound uraemic toxins by haemodialysis.
Niwa T
Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
[TBL] [Abstract][Full Text] [Related]
14. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.
Deguchi T; Isozaki K; Yousuke K; Terasaki T; Otagiri M
J Neurochem; 2006 Feb; 96(4):1051-9. PubMed ID: 16445853
[TBL] [Abstract][Full Text] [Related]
15. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
[TBL] [Abstract][Full Text] [Related]
16. Evolution of protein-bound uraemic solutes during predilution haemofiltration.
Meert N; Beerenhout C; Schepers E; Glorieux G; Kooman J; Vanholder R
J Nephrol; 2009; 22(3):352-7. PubMed ID: 19557711
[TBL] [Abstract][Full Text] [Related]
17. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
Niwa T
Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
[TBL] [Abstract][Full Text] [Related]
18. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.
Sun H; Huang Y; Frassetto L; Benet LZ
Drug Metab Dispos; 2004 Nov; 32(11):1239-46. PubMed ID: 15286055
[TBL] [Abstract][Full Text] [Related]
19. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
[TBL] [Abstract][Full Text] [Related]
20. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
